Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle

Background: The development of anti-drug antibodies (ADA) in patients treated with therapeutic proteins can result in treatment failure. The clinically most relevant fraction of these antibodies are the neutralizing anti-drug antibodies (NAb) that block the pharmacological function of the drug. Cons...

Full description

Bibliographic Details
Main Authors: Mohsin El Amrani, Camiel Göbel, Annelies C. Egas, Stefan Nierkens, C. Erik Hack, Alwin D.R. Huitema, Erik M. van Maarseveen
Format: Article
Language:English
Published: Elsevier 2019-04-01
Series:Journal of Translational Autoimmunity
Online Access:http://www.sciencedirect.com/science/article/pii/S2589909019300048